EQRX Key Statistics, Chart & Performance
The current stock price of EQRX is 2.34 USD. In the past month the price increased by 5.41%. In the past year, price decreased by -36.24%.
EQRX Latest News, Press Relases and Analysis
EQRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About EQRX
Company Profile
EQRx, Inc. is a pharmaceutical company, which engages in developing and delivering innovative medicines to patients having chronic conditions. The company is headquartered in Cambridge, Massachusetts and currently employs 362 full-time employees. The company went IPO on 2021-04-09. The firm is engaged in developing medicines for some of the prevalent disease areas, including cancer and immune-inflammatory conditions. The firm brands include EQRx and Remaking Medicine. The firm's pipeline is comprised of approximately 10 programs, including both small molecules and biologics, with five clinical-stage programs, and several disclosed and undisclosed preclinical and drug engineering programs. Its clinical programs include Aumolertinib (EQ143), Lerociclib (EQ132), and Sugemalimab (EQ165). Aumolertinib (EQ143) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lerociclib (EQ132) is a novel and oral small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Sugemalimab (EQ165, also known as CS1001) is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody.
Company Info
EQRX INC
50 Hampshire Street
Cambridge MASSACHUSETTS US
Employees: 362
Phone: 16173152255.0
EQRX INC / EQRX FAQ
What does EQRX do?
EQRx, Inc. is a pharmaceutical company, which engages in developing and delivering innovative medicines to patients having chronic conditions. The company is headquartered in Cambridge, Massachusetts and currently employs 362 full-time employees. The company went IPO on 2021-04-09. The firm is engaged in developing medicines for some of the prevalent disease areas, including cancer and immune-inflammatory conditions. The firm brands include EQRx and Remaking Medicine. The firm's pipeline is comprised of approximately 10 programs, including both small molecules and biologics, with five clinical-stage programs, and several disclosed and undisclosed preclinical and drug engineering programs. Its clinical programs include Aumolertinib (EQ143), Lerociclib (EQ132), and Sugemalimab (EQ165). Aumolertinib (EQ143) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lerociclib (EQ132) is a novel and oral small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Sugemalimab (EQ165, also known as CS1001) is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody.
What is the current price of EQRX stock?
The current stock price of EQRX is 2.34 USD. The price decreased by -2.09% in the last trading session.
Does EQRX stock pay dividends?
EQRX does not pay a dividend.
What is the ChartMill rating of EQRX INC stock?
EQRX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting EQRX stock to perform?
7 analysts have analysed EQRX and the average price target is 2.14 USD. This implies a price decrease of -8.46% is expected in the next year compared to the current price of 2.34.
Should I buy EQRX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on EQRX.
Who owns EQRX INC?
You can find the ownership structure of EQRX INC (EQRX) on the Ownership tab.
EQRX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to EQRX. When comparing the yearly performance of all stocks, EQRX is a bad performer in the overall market: 74.99% of all stocks are doing better.
EQRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EQRX. EQRX has a great financial health rating, but its profitability evaluates not so good.
EQRX Financial Highlights
Over the last trailing twelve months EQRX reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS decreased by -62.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.04% | ||
| ROE | -21.05% | ||
| Debt/Equity | 0 |
EQRX Forecast & Estimates
7 analysts have analysed EQRX and the average price target is 2.14 USD. This implies a price decrease of -8.46% is expected in the next year compared to the current price of 2.34.